These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26231785)

  • 1. AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.
    Wu J; Fu J; Zhang M; Liu D
    J Hematol Oncol; 2015 Aug; 8():96. PubMed ID: 26231785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma.
    Rothe A; Sasse S; Topp MS; Eichenauer DA; Hummel H; Reiners KS; Dietlein M; Kuhnert G; Kessler J; Buerkle C; Ravic M; Knackmuss S; Marschner JP; Pogge von Strandmann E; Borchmann P; Engert A
    Blood; 2015 Jun; 125(26):4024-31. PubMed ID: 25887777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30
    Kerbauy LN; Marin ND; Kaplan M; Banerjee PP; Berrien-Elliott MM; Becker-Hapak M; Basar R; Foster M; Garcia Melo L; Neal CC; McClain E; Daher M; Nunez Cortes AK; Desai S; Inng Lim FW; Mendt MC; Schappe T; Li L; Shaim H; Shanley M; Ensley EL; Uprety N; Wong P; Liu E; Ang SO; Cai R; Nandivada V; Mohanty V; Miao Q; Shen Y; Baran N; Fowlkes NW; Chen K; Muniz-Feliciano L; Champlin RE; Nieto YL; Koch J; Treder M; Fischer W; Okamoto OK; Shpall EJ; Fehniger TA; Rezvani K
    Clin Cancer Res; 2021 Jul; 27(13):3744-3756. PubMed ID: 33986022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells.
    Reusch U; Burkhardt C; Fucek I; Le Gall F; Le Gall M; Hoffmann K; Knackmuss SH; Kiprijanov S; Little M; Zhukovsky EA
    MAbs; 2014; 6(3):728-39. PubMed ID: 24670809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma.
    Bartlett NL; Herrera AF; Domingo-Domenech E; Mehta A; Forero-Torres A; Garcia-Sanz R; Armand P; Devata S; Izquierdo AR; Lossos IS; Reeder C; Sher T; Chen R; Schwarz SE; Alland L; Strassz A; Prier K; Choe-Juliak C; Ansell SM
    Blood; 2020 Nov; 136(21):2401-2409. PubMed ID: 32730586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells.
    Pahl JHW; Koch J; Götz JJ; Arnold A; Reusch U; Gantke T; Rajkovic E; Treder M; Cerwenka A
    Cancer Immunol Res; 2018 May; 6(5):517-527. PubMed ID: 29514797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of heterotransplanted Hodgkin's tumors in SCID mice by a combination of human NK or T cells and bispecific antibodies.
    Renner C; Pfreundschuh M
    J Hematother; 1995 Oct; 4(5):447-51. PubMed ID: 8581383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial.
    Sasse S; Bröckelmann PJ; Momotow J; Plütschow A; Hüttmann A; Basara N; Koenecke C; Martin S; Bentz M; Grosse-Thie C; Thorspecken S; de Wit M; Kobe C; Dietlein M; Tresckow BV; Fuchs M; Borchmann P; Engert A
    Leuk Lymphoma; 2022 Aug; 63(8):1871-1878. PubMed ID: 35848865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted immunotherapy in Hodgkin lymphoma.
    Hutchings M
    Blood; 2015 Jun; 125(26):3967-8. PubMed ID: 26113529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity.
    Ellwanger K; Reusch U; Fucek I; Wingert S; Ross T; Müller T; Schniegler-Mattox U; Haneke T; Rajkovic E; Koch J; Treder M; Tesar M
    MAbs; 2019 Jul; 11(5):899-918. PubMed ID: 31172847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells.
    Heuser C; Guhlke S; Matthies A; Bender H; Barth S; Diehl V; Abken H; Hombach A
    Int J Cancer; 2004 Jun; 110(3):386-94. PubMed ID: 15095304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating Hodgkin's disease with bispecific antibodies: Both patients and antibody are limiting.
    Fisher RI
    Clin Cancer Res; 2001 Jul; 7(7):1835-6. PubMed ID: 11448891
    [No Abstract]   [Full Text] [Related]  

  • 13. CD30 as a therapeutic target for lymphoma.
    Schirrmann T; Steinwand M; Wezler X; Ten Haaf A; Tur MK; Barth S
    BioDrugs; 2014 Apr; 28(2):181-209. PubMed ID: 24043362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines.
    Hartmann F; Renner C; Jung W; da Costa L; Tembrink S; Held G; Sek A; König J; Bauer S; Kloft M; Pfreundschuh M
    Clin Cancer Res; 2001 Jul; 7(7):1873-81. PubMed ID: 11448899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies.
    Tun AM; Ansell SM
    Cancer Treat Rev; 2020 Aug; 88():102042. PubMed ID: 32521386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma.
    Gerber HP
    Biochem Pharmacol; 2010 Jun; 79(11):1544-52. PubMed ID: 20096666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First Hodgkin cell line L428 and the CD30 antigen: their role for diagnostic and treatment of CD30-positive neoplasms.
    Stein H; Diehl V
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):1-11. PubMed ID: 24287063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.
    Schnell R; Dietlein M; Staak JO; Borchmann P; Schomaecker K; Fischer T; Eschner W; Hansen H; Morschhauser F; Schicha H; Diehl V; Raubitschek A; Engert A
    J Clin Oncol; 2005 Jul; 23(21):4669-78. PubMed ID: 16034043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
    Hochberg J; El-Mallawany NK; Cairo MS
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies.
    Sforzini S; Bolognesi A; Meazza R; Marciano S; Tazzari PL; Stein H; Stirpe F; Ferrini S
    J Hematother; 1995 Oct; 4(5):429-32. PubMed ID: 8581380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.